G. Lieberman

1.1k total citations
9 papers, 231 citations indexed

About

G. Lieberman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, G. Lieberman has authored 9 papers receiving a total of 231 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in G. Lieberman's work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (4 papers) and Cell death mechanisms and regulation (2 papers). G. Lieberman is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (4 papers) and Cell death mechanisms and regulation (2 papers). G. Lieberman collaborates with scholars based in United States and Germany. G. Lieberman's co-authors include Harold J. Burstein, Dennis J. Slamon, Eric P. Winer, Paula Klein, Roy S. Herbst, Peter J. O’Dwyer, Scot Ebbinghaus, Gail Eckhardt, Razelle Kurzrock and William Novotny and has published in prestigious journals such as Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

G. Lieberman

9 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Lieberman United States	5	148	99	85	43	40	9	231
Elisa Minenza Italy	9	182 1.2×	59 0.6×	117 1.4×	32 0.7×	31 0.8×	12	245
Pablo Tolosa Spain	8	154 1.0×	61 0.6×	91 1.1×	30 0.7×	50 1.3×	36	229
Federica Predolini United States	9	148 1.0×	81 0.8×	50 0.6×	47 1.1×	35 0.9×	12	275
Ashish Noronha Israel	7	95 0.6×	126 1.3×	66 0.8×	37 0.9×	30 0.8×	11	208
Grégoire Marret France	8	119 0.8×	96 1.0×	74 0.9×	13 0.3×	48 1.2×	24	231
Amy Hankin United States	7	161 1.1×	77 0.8×	78 0.9×	14 0.3×	41 1.0×	28	210
David König Switzerland	7	145 1.0×	83 0.8×	95 1.1×	14 0.3×	34 0.8×	26	247
Karie Runcie United States	6	114 0.8×	101 1.0×	66 0.8×	62 1.4×	24 0.6×	27	227
Maxime Borgeaud Switzerland	5	171 1.2×	88 0.9×	150 1.8×	15 0.3×	52 1.3×	14	285
Frank Ziemann Germany	8	113 0.8×	121 1.2×	57 0.7×	19 0.4×	58 1.4×	10	259

Countries citing papers authored by G. Lieberman

Since Specialization

Citations

This map shows the geographic impact of G. Lieberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Lieberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Lieberman more than expected).

Fields of papers citing papers by G. Lieberman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Lieberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Lieberman. The network helps show where G. Lieberman may publish in the future.

Co-authorship network of co-authors of G. Lieberman

This figure shows the co-authorship network connecting the top 25 collaborators of G. Lieberman. A scholar is included among the top collaborators of G. Lieberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Lieberman. G. Lieberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Herbst, Roy S., Scot Ebbinghaus, Michael S. Gordon, et al.. (2006). A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Journal of Clinical Oncology. 24(18_suppl). 3013–3013. 77 indexed citations

Ueland, F., Annette Bicher, Don S. Dizon, et al.. (2006). A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): Preliminary safety data. Journal of Clinical Oncology. 24(18_suppl). 13001–13001. 3 indexed citations

Herbst, Roy S., David S. Mendelson, Sabine Eckhardt, et al.. (2006). Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. Journal of Clinical Oncology. 24(18_suppl). 3047–3047. 27 indexed citations

Burstein, Harold J., G. Lieberman, Dennis J. Slamon, Eric P. Winer, & Paula Klein. (2005). Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Annals of Oncology. 16(11). 1772–1777. 104 indexed citations

Press, MF, R. Mass, Jane Sullivan‐Halley, et al.. (2005). Association of topoisomerase II-alpha (TOP2A) gene amplification with responsiveness to anthracycline-containing chemotherapy among women with metastatic breast cancer entered in the Herceptin H0648g pivotal clinical trial. Journal of Clinical Oncology. 23(16_suppl). 9543–9543. 7 indexed citations

Anderson, Stewart, Jessica Reddy, N. Shesh, G. Lieberman, & Pamela Klein. (2004). Concordance between central and local lab IHC and FISH HER2 testing in a community-based trial of first-line trastuzumab plus a taxane in HER2+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 22(14_suppl). 9580–9580. 2 indexed citations

Oster, Gerry, et al.. (2004). Cost-effectiveness of HER-2 testing strategies to select women with metastatic breast cancer (MBC) for treatment with trastuzumab. Journal of Clinical Oncology. 22(14_suppl). 768–768. 1 indexed citations

Yeon, Christina, DJ Slamon, Reema Patel, et al.. (2004). Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT). Journal of Clinical Oncology. 22(14_suppl). 680–680. 6 indexed citations

Yeon, Christina, Reema Patel, Alan Cartmell, et al.. (2004). Clinical benefit of trastuzumab (H) among patients with HER2-positive metastatic breast cancer (MBC) not achieving objective responses when treated with H plus chemotherapy (CT). Journal of Clinical Oncology. 22(14_suppl). 680–680. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact